{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:50:50Z","timestamp":1772121050153,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jhep.2014.04.021","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T09:46:56Z","timestamp":1398505616000},"page":"482-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis"],"prefix":"10.1016","volume":"61","author":[{"given":"Raoel","family":"Maan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan J.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman F.","family":"Zangneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"de Knegt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart J.","family":"Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.04.021_b0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.04.021_b0010","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0168-8278(02)00274-X","article-title":"Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis","volume":"37","author":"Giannini","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.04.021_b0015","first-page":"381","article-title":"Thrombocytopenia in chronic hepatitis C","volume":"19","author":"Olariu","year":"2010","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1016\/j.jhep.2014.04.021_b0020","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jhep.2010.08.018","article-title":"Platelet production and destruction in liver cirrhosis","volume":"54","author":"Pradella","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.04.021_b0025","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.04.021_b0030","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-2036.2006.02889.x","article-title":"Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options","volume":"23","author":"Giannini","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.04.021_b0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.04.021_b0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.04.021_b0045","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.04.021_b0050","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0149-2918(11)00022-1","article-title":"A review of the treatment of chronic hepatitis C virus infection in cirrhosis","volume":"32","author":"Vezali","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2014.04.021_b0055","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.04.021_b0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","article-title":"Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C","volume":"132","author":"Shiffman","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.04.021_b0065","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0070","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0075","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0080","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0085","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.04.021_b0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1478-3231.2011.02703.x","article-title":"2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines","volume":"32","author":"European Association of the Study of the Liver","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2014.04.021_b0100","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"American Association for the Study of Liver. Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.04.021_b0105","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.12185","article-title":"The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection","volume":"21","author":"van der Meer","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.04.021_b0110","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0115","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-0037-1613840","article-title":"A novel approach to the assessment of variations in the human platelet count","volume":"83","author":"Buckley","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jhep.2014.04.021_b0120","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.04.021_b0125","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1478-3231.2012.02798.x","article-title":"Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy","volume":"32","author":"Giannini","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2014.04.021_b0130","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.04.021_b0135","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-230X-12-7","article-title":"Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts","volume":"12","author":"Lin","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2014.04.021_b0145","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.04.021_b0155","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.04.021_b0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2010.04.013","article-title":"Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C","volume":"53","author":"Roomer","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.04.021_b0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.04.021_b0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bpg.2012.09.009","article-title":"Natural history of acute and chronic hepatitis C","volume":"26","author":"Maasoumy","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2014.04.021_b0175","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1016\/j.cgh.2011.03.002","article-title":"Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection","volume":"9","author":"Reiberger","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.04.021_b0180","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/cncr.22242","article-title":"Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma","volume":"107","author":"Lu","year":"2006","journal-title":"Cancer"},{"issue":"442\u2013452","key":"10.1016\/j.jhep.2014.04.021_b0205","first-page":"e441","article-title":"Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy","volume":"146","author":"Afdhal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.04.021_b0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2036.2007.03511.x","article-title":"Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection","volume":"26","author":"Afdhal","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.04.021_b0195","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1517\/14656566.2013.775249","article-title":"Eltrombopag in patients with chronic liver disease","volume":"14","author":"Giannini","year":"2013","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814002840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814002840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:58Z","timestamp":1759174378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814002840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0168827814002840"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.04.021","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718369815.793494879","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}